The present study was designed to compare ketoprofen 150 mg daily with ibuprofen 1,200 mg daily in the treatment of rheumatoid arthritis.
Discussion
The present study was designed to compare ketoprofen 150 mg daily with ibuprofen 1,200 mg daily in the treatment of rheumatoid arthritis. Cromie (1963) pointed out that gross alterations in formulations of trial drugs could possibly alter bioavailability, and theoretically the change in presentation of ibuprofen in the present study might have affected its bioavailability and reduced its effectiveness. However, the manufacturers (Boots) thought that the 200 mg capsules of ibuprofen used in this study were suitable for clinical trial purposes.
The results suggest that ketoprofen has analgesic and antiinflammatory activity superior to ibuprofen. It is noted particularly that statistically significant differences in activity, favouring ketoprofen, were obtained even with the comparatively small number of patients used in this study. These results are consistent with those of Owen-Smith and Burry (1972) and Gyory et al. (1972) , who showed, respectively, indomethacin 75 mg to have greater activity than ibuprofen 1,200 mg, and ketoprofen 100 mg to have comparable activity with indomethacin 100 mg. Cardoe (1969) and Goldberg et al. (1971) reported an overall reduction in E.S.R. in patients with rheumatoid arthritis treated with ibuprofen. The reduction in E.S.R. in the present study favoured ibuprofen (P < 0 05), despite the reverse finding for joint circumference.
A factor influencing the therapeutic efficacy of drugs, both in clinical trials and in other clinical situations, is drug interaction. Ketoprofen has been shown to have no effect on hepatic drugmetabolizing enzymes, based on a study of plasma-clearance of antipyrine (Cathcart et al., 1973) , and is unlikely therefore to interact with drugs metabolized by the liver.
An important consideration in assessing the value of a new drug for treatment of rheumatoid arthritis is incidence of adverse reactions. A drawback to the use of indomethacin, a powerful analgesic and anti-inflammatory agent, is a relatively high incidence of side effects. Ibuprofen has been found to be better tolerated, but its therapeutic efficacy has been questioned (Hart, 1972; Owen-Smith and Burry, 1972 (G. Gomez, personal communication, 1973) . These findings are consistent with the present results in which side effects of ketoprofen and ibuprofen were found to be comparable and not serious.
In conclusion, the present study has shown that analgesic and anti-inflammatory activity of ketoprofen is significantly superior to that of ibuprofen, while adverse reactions of the two drugs are comparable and not serious. This is further evidence that ketoprofen may be a useful drug in the clinical management of rheumatoid arthritis.
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Results
The results are shown in No penicillin-resistant strains were found, apart from two Lancefield group D strains which produced reduced zones and were not fully sensitive but did not grow on MacConkey medium. Nine similar strains were encountered in 1965-7. Erythromycin-resistant strains continue to be rare, only four being seen in the second five years of the survey. These came from a leg ulcer in a geriatric patient, a vaginal swab and a throat swab in hospital patients, and an ear swab from general practice. Two of these were also resistant to clindamycin (2 /tg disc) and one to lincomycin (2 ug disc) before clindamycin was routinely tested in this laboratory. Four other strains were reported in the earlier part of this survey, making eight in 10 years from a total of 6,012 isolations. In addition, three others regarded as partially sensitive were seen in the period 1965-7. Lancefield grouping of 44 strains from the last five years show 48% to belong to group A, 11% to group B, 2% to C, 4.5% to D, 14% to G, and 20% to none of these groups. These figures again show a slight fall in the proportion of group A strains but the numbers tested are too small to be of significance.
Discussion
The final two years of this survey, 1971 and 1972, show a much lower incidence of tetracycline-resistant beta-haemolytic streptococci than the previous eight years. The incidence for the first five-year period 1963-7 was 31-8%, and for the second five years 1968-72 16-2%. The period 1971-2 shows an incidence of only 8-8%. Ear infections, which previously carried the highest percentage of tetracycline-resistant streptococci in this area (70% in 1963-4) , no longer yield the highest proportion of these organisms. The figures for 1971-2 being only 13-3%-equal to that shown by wound infections and below the level of 20% found for vaginal swabs, which now have the highest rate.
Though throat swabs at 5-2% yield a low percentage of these organisms they are still the site of the greatest number of isolations followed by vaginal swabs and wound and skin infections. The vulva, perineum, and skin infections seem to have become major sources of these streptococci.
The material for the last two years when broken down into the sources of referral of the specimens-general practice (499 specimens), inpatients (573), outpatients (333), and nurses (70) -shows pronounced falls from the figures for all these groups in 1965-7-that is, general practice 7-6% (35-3%), inpatients 7-85% (33 5%), outpatients 13.2% (29%), and nurses 5-7% (16%) (earlier figures are shown in parentheses). It is to be hoped that this decline of the tetracycline-resistant streptococcus is due to greater selectivity in the prescribing of tetracycline, and that this situation will be maintained. Penicillin remains the drug of choice for beta-haemolytic streptococcal infections, with erythromycin and clindamycin as alternatives for patients allergic to penicillin.
